1. Grant BF, Hasin DS, Chou SP, Stinson FS, Dawson DA. Nicotine dependence and psychiatric disorders in the United States: results from the national epidemiologic survey on alcohol and related conditions. Arch Gen Psychiatry. 2004;61:1107–1115. [PubMed] 2. Lasser K, Boyd JW, Woolhandler S, Himmelstein DU, McCormick D, Bor DH. Smoking and mental illness: a population-based prevalence study. JAMA. 2000;284:2606–2610. [PubMed]
3. Federal Trade Commission. Federal Trade Commission Cigarette Report for 2003. Washington, DC: Federal Trade Commission; 2005.
4. Womach J.
5. Hughes JR. Possible effects of smoke-free inpatient units on psychiatric diagnosis and treatment. J Clin Psychiatry. 1993;54:109–114. [PubMed] 6. Poirier MF, Canceil O, Bayle F, et al. Prevalence of smoking in psychiatric patients. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26:529–537. [PubMed] 7. Levin ED, Wilson W, Rose JE, McEvoy J. Nicotine-haloperidol interactions and cognitive performance in schizophrenics. Neuropsychopharmacology. 1996;15:429–436. [PubMed] 8. Barak Y, Achiron A, Mandel M, Mirecki I, Aizenberg D. Reduced cancer incidence among patients with schizophrenia. Cancer. 2005;104:2817–2821. [PubMed] 9. Dalack GW, Meador-Woodruff JH. Smoking, smoking withdrawal and schizophrenia: case reports and a review of the literature. Schizophr Res. 1996;22:133–141. [PubMed] 10. Sandyk R, Kay SR. Tobacco addiction as a marker of age at onset of schizophrenia. Int J Neurosci. 1991;57:259–262. [PubMed] 11. Bero L. Implications of the tobacco industry documents for public health and policy. Annu Rev Public Health. 2003;24:267–288. [PubMed] 12. Bero LA. Tobacco industry manipulation of research. Public Health Rep. 2005;120:200–208. [PMC free article] [PubMed]
14. Lewis NDC. Research in Dementia Praecox.
19. Lincoln JE. Schizophrenics.
20. Perrin GM, Pierce IR. Psychosomatic aspects of cancer: a review. Psychosom Med. 1959;21:397–421. [PubMed] 21. Breen MJ. The incidence of lung cancer among schizophrenic males versus nonschizophrenic males. A dissertation presented to the graduate faculty of the School of Education United States International University. 1981 Bates No. 504848496/8514. Available at: http://legacy.library.ucsf.edu/tid/cuq18c00. 22. Fox BH, Howell MA. Cancer risk among psychiatric patients: a hypothesis. Int J Epidemiol. 1974;3:207–208. [PubMed] 23. Tsuang MT, Perkins K, Simpson JC. Physical diseases in schizophrenia and affective disorder. J Clin Psychiatry. 1983;44:42–46. [PubMed] 24. Harris AE. Physical disease and schizophrenia. Schizophr Bull. 1988;14:85–96. [PubMed]
25. Bahnson CB. Letter to Dr. Hockett Requesting Continued Research Funding on Dr. Kissen's Unit in Glasgow.
26. Hetsko C. Memo to William W. Shinn Confirming American Brands’ $8,000 Contribution to Dr. Claus Bahnson's Project.
27. Holtzman A. Special Project—Dr. Claus Bahnson.
29. Colby FG. Report on trip to Germany.
31. Wakeham H. Letter about Doubts of Dr. Bahnson's Research Involvement.
32. Todd GF. Private Letter No. 12 to Mr. Addison Yeaman.
33. Gaudet FJ, Owen HE. Application for Research Grant Exploring Cancer Rates and Cigarette Use among Different Types of Schizophrenia.
34. Lavietes MH. Cigarette Smoking in Schizophrenic Patients.
35. Hockett RC. Research Application from Frederick J. Gaudet.
36. McAllister HC. Decline of Research Support for Dr. Marc Lavietes.
37. CTR Collection. Confidential Report Scientific Advisory Board Meeting New York, NY.
39. Hockett RC. Letter to Dr. Taguiri Concerning Research Proposals, Including Smoking and High Academic Achievement.
40. Wilson EB. Letter to Dr. Hockett.
41. Dalton SO, Laursen TM, Mellemkjaer L, Johansen C, Mortensen PB. Risk for cancer in parents of patients with schizophrenia. Am J Psychiatry. 2004;161:903–908. [PubMed] 42. Lichtermann D, Ekelund J, Pukkala E, Tanskanen A, Lonnqvist J. Incidence of cancer among persons with schizophrenia and their relatives. Arch Gen Psychiatry. 2001;58:573–578. [PubMed] 43. Goff DC, Sullivan LM, McEvoy JP, et al. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr Res. 2005;80:45–53. [PubMed] 44. Himelhoch S, Lehman A, Kreyenbuhl J, Daumit G, Brown C, Dixon L. Prevalence of chronic obstructive pulmonary disease among those with serious mental illness. Am J Psychiatry. 2004;161:2317–2319. [PubMed]
45. Gullotta WSA Categorization form Smoking Behavior: Clinical Depression and Schizophrenia.
46. Southwick MA. Literature Search: Schizophrenia and Nicotine.
47. Glantz SA, Slade J, Bero LA, Hanauer P, Barnes DE. The Cigarette Papers. Berkeley, Calif: University of California Press; 1996.
48. Deithelm PA, Rielle J-C, McKee M. The whole truth and nothing but the truth? The research that Philip Morris did not want you to see. Lancet. 2005;366:86–92. [PubMed]
49. Knott V. Tobacco Smoking as a Coping Mechanism in Psychiatric Patients: Psychological, Behavioral and Physiological Investigations Phase I.
50. Knott V. Research Proposal. Tobacco Smoking as a Coping Mechanism in Psychiatric Patients: Psychological, Behavioral and Physiological Investigations.
51. Crawford DA. Letter to Dr. R. Suber in the Consideration Dr. Knott's Research Proposal.
52. Barnes DE, Bero LA. Industry-Funded Research and Conflict of Interest: An Analysis of Research Sponsored by the Tobacco Industry through the Center for Indoor Air Research. J Health Polit Policy Law. 1996;21:515–542. [PubMed] 53. Bero L, Barnes DE, Hanauer P, Slade J, Glantz SA. Lawyer control of the tobacco industry's external research program. The Brown and Williamson documents. JAMA. 1995;274:241–247. [PubMed]
54. Amey MB, Wong DF. Application for Research Grant: In Vivo Studies of Nicotinic Cholinergic Receptors in the Human Brain.
55. Smith C. Comments on Dr. Wang's Grant Proposal: In Vivo Studies of Nicotinic Cholinergic Receptors in the Human Brain.
56. Stone D. Second Renewal Application: In Vivo Studies of Nicotinic Cholinergic Receptors in the Human Brain.
57. Gray JA. CTR Progress Report Mediation by Catecholamine Systems of Effects of Nicotine on Behaviours. 1997.
58. Gray JA. Project Details: Nicotine Neuroprotection and Animal Models of Neurodegenerative Cognitive Dysfunction.
59. Gray JA, Joseph MH, Hemsley DR, et al. The role of mesolimbic dopaminergic and retrohippocampal afferents to the nucleus accumbens in latent inhibition: implications for schizophrenia. Behav Brain Res. 1995;71:19–31. Bates No. 50379603/9615. Available at: http://legacy.library.ucsf.edu/tid/iek98d00. [PubMed] 60. Postma P, Gray JA, Sharma T, et al. A behavioural and functional neuroimaging investigation into the effects of nicotine on sensorimotor gating in healthy subjects and persons with schizophrenia. Psychopharmacology (Berl) 2006;184:589–599. [PubMed]
61. Mangan GL. Application to Philip Morris USA for Research Funding.
62. Mangan GL. Facsimile Transmission Header Sheet Completion of Philip Morris Research Programme at the University of Auckland.
63. Hedqvist P, Svensson TH. Research Grant Application. Nicotine Dependence in Psychiatric Illness: an Experimental Study.
64. Glenn JF. Brief Site Visit Report.
65. Svensson TH. CTR Progress Report (for Competing Renewal Application) Nicotinic Dependence in Psychiatric Illness: an Experimental Study.
66. Svensson TH, Mathe JM, Andersson JL, Nomikos GG, Hildebrand BE, Marcus M. Mode of action of atypical neuroleptics in relation to the phencyclidine model of schizophrenia: role of 5-HT2 receptor and alpha1-adrenoreceptor antagonism. J Clin Psychopharmacol. 1995;15(suppl 1):11S, 18S. Bates No. 50733819/3826. Available at: http://legacy.library.ucsf.edu/tid/ixi46d00. [PubMed] 67. Nisell M, Nomikos GG, Svensson TH. Systemic nicotine-induced dopamine release in the rat nucleus accumbens is regulated by nicotinic receptors in the ventral tegmental area. Synapse. 1994;16:36–44. Bates No. 50708314/8314. Available at: http://legacy.library.ucsf.edu/tid/luf46d00. [PubMed] 68. Nisell M, Nomikos GG, Svensson TH. Infusion of nicotine in the ventral tegmental area or the nucleus accumbens of the rat differentially affects accumbal dopamine release. Pharmacol Toxicol. 1994;75:348–352. [PubMed] 69. Nisell M, Nomikos GG, Svensson TH. Nicotine dependence, midbrain dopamine systems and psychiatric disorders. Pharmacol Toxicol. 1995;76:157–162. [PubMed] 70. Grillner P, Bonci A, Svensson TH, Bernardi G, Mercuri NB. Presynaptic muscarinic (M3) receptors reduce excitatory transmission in dopamine neurons of the rat mesencephalon. Neuroscience. 1999;91:557–565. [PubMed]
71. Furlong P, Tanabe J. Project Proposal Effects of Nicotine on Brain Activation.
72. Kassman A. SRRC Proposals: Tanabe, Bilder & Lajtha/Friedman.
73. Gullotta FP. Bilder/Lajtha Grant.
74. Philip Morris Collection. Approval of Grant Proposal Entitled: “Effects of Nicotine on Brain Activation”.
75. McAlpin L. Philip Morris Voucher.
76. Bidler RM, Lajtha A, Thomas T. Nicotine Effects on Cognition: Meta-analysis and Implications for Neuroimaging.
77. de Leon J. Epidemiology of Tobacco Use in Psychiatric Disorders.
78. Esser AH, Lee MG. Application for Research Grant: The Social Use of Tobacco.
79. Hoyt WT. Research Funding Decline for Dr. Aristide H. Esser.
80. Smith RC. Effects of Smoking on Blood Levels of Neuroleptic and Antidepressant Drugs.
81. Goff DC. Nicotine in Schizophrenia.
82. Barclay GL, Devlin RJ, Grant FW, McDonald RD, Ozerengin MF, Voorhees W. Application for Research Grant: Vitamin “C” Depletion in Tobacco Smokers. Influence on Psychopathology and Therapeutic Drug Requirements in a Mental Hospital Setting.
83. Deutsch SI. Effect of Nicotine in an Animal Model of Schizophrenia.
84. Lachman H. Molecular Genetic Analysis of Aggression in Rats.
85. Javaid JI, Longone P, Pesold C. Functional Characterization of Neuronal Nicotinic Acetylcholine Receptor (NACHR) Subtypes.
86. Liu Y, Nisbett N. Research Grant Application: Physiological Role(s) of SNAP-25.
87. Nawa H. Neurotransmitter Differentiation of Neural Precursors in the Brain.
88. Paskevich PA, Tarazi FI. Research Grant Application Localization and Regulation of Neurotensin Receptor and Gene Expression.
89. Regehr WG. The Control of Synaptic Transmission in the Mammalian Brain by Presynaptic Waveform.
90. Arnason B. Drug abuse and the Dopamine Transporters.
92. RJ Reynolds Collection. Review of a Proposal Submitted by Sheila Carter, M.D. 1985.
93. Callery PS. Metabolites of Tobacco Constituents Related to GABA as Potential Therapeutic Entities.
94. Ellis C. WWSA Project Justification Role of Neuronal Nicotinic Receptors in Brain Function.
95. Hayes AW. Letter to Dr. D.A. Crawford Concerning Review of Research Grants.
96. Hockett RC. Research Proposal Decline for Robert C. Smith.
97. Glenn JF. Rejection for Dr. Neve's Research Proposal: Drug Abuse and the Dopamine Transporter.
98. Glenn JF. Decline of Dr. Yuechueng Liu's Research Proposal: Physiological Role(s) of SNAP-25.
99. Glenn JF. Rejection of Dr. F. Tarazi's Research Proposal: Localization and Regulation of Neurotensin Receptor and Gene Expression.
100. McAllister HC. Decline of Research Funds for Donald C. Goff.
101. McAllister HC. Decline of Support for Dr. Wade Regehr's Research Proposal.
102. Lippiello PM, Fluhler EN. Nicotine Receptor Pharmacology.
103. Lillpiello PM, Caldwell WS, DeBethizy JD, Smith CJ, Pritchard WS. Progress Report on the RJRT-Hoechst-Roussel Collaborative Scientific Program.
104. Wellesley MA. Corporate Overview of Pharmaceutical Related Technologies of the R.J. Reynolds Tobacco Company.
105. Targacept. Targacept Key Messages.
106. Vagg R, Chapman S. Nicotine analogues: a review of tobacco industry research interests. Addiction. 2005;100:701–712. [PubMed]
107. Targacept. Targacept Pharmaceutical Technologies of the R.J. Reynolds Tobacco Company.
108. Targacept. Targacept Leader in Neuronal Nicotinic Receptor-Based pharmaceutical R&D.
110. RJ Reynolds Collection. Nicotinic Compound Q&A.
112. Philip Morris Collection. Advertisement: schizophrenic
113. Gilbert DG. Smoking: Individual Differences, Psychopathology, and Emotion. Washington, DC: Taylor & Francis; 1995.
115. Tobacco Institute Collection. Active Projects.
116. American Tobacco Collection
117. Council for Tobacco Research
118. Nixon G. Fax
119. Philip Morris Collection. Pharmacology of Nicotine.
120. Levin ED. Thank You to Robert F. Gertenbach for $75,000/year Grant Concerning the Behavioral and Neural Mechanisms Underlying Nicotine-Induced Cognitive Facilitation.
121. Levin ED. Thank You to Dr. Robert F. Gertenbach for $85,000 Grant to Investigate Beneficial Effect Nicotine Has on Memory Function.
122. Levin ED. Thank You for $43,777 Gift to Support Work on Nicotinic Psychopharmacology at Duke.
123. Levin ED. Thank You to Dr. McAllister for $92,000 Grant to Investigate Beneficial Effect Nicotine Has on Memory Function.
124. Levin ED, Karan L, Rosecrans J. Nicotine: an addictive drug with therapeutic potential. Med Chem Res. 1993:509–513.
125. Levin ED, Rezvani AH. Development of nicotinic drug therapy for cognitive disorders. Eur J Pharmacol. 2000;393:141–146. [PubMed] 126. Levin ED, Rezvani AH. Nicotinic treatment for cognitive dysfunction. Curr Drug Targets. 2002;1:423–431. [PubMed]
127. Levin ED. New York, NY: CRC Press. Chapter 11 by Joseph McEvoy Nicotine and Schizophrenia; 2001. Nicotinic receptors in the nervous system; pp. 227–234.
128. Levin ED. Letter to RJR's Dr. J. Donald DeBethizy Requesting $15,000 for Duke's Nicotine Research Symposium.
129. Levin ED. Thank You to Dr. Frank Gullotta of Phillip Morris-USA for $10,000 Donation to Duke Nicotine Conference.
130. Levin ED. Request for Monetary Contribution for Duke Nicotine Conference from Dr. Frank Gullotta of Phillip Morris-USA.
131. Levin ED. First Annual Duke Nicotine Research Symposium. Neurobehavioral Effects of Nicotine.
132. Philip Morris Collection. Synopsis of the 5th Annual Duke Nicotine Research Conference.
133. Rose JE, Levin ED. Duke Nicotine Research Conference.
134. Brandt L, Brearley E. Future Events: 5th Annual Duke Nicotine Research Conference, Targeting Nicotinic Treatments
135. Duke University. Third Annual Duke Nicotine Research Conference, Nicotinic Systems: Molecular Heterogenecity And Individual Differences Program.
136. Lipowicz PJ. 6th Duke Nicotine Research Conference Trip Report.
137. Lukas RJ, Bencherif M, Eisenhour CM. Regulation by Nicotine of its Own Receptors.
138. Bero LA, Galbraith A, Rennie D. Sponsored symposia on environmental tobacco smoke. JAMA. 1994;271:612–617. [PubMed]
139. Cloninger CR. The State of Texas vs. the American Tobacco Company, et al. Videotaped Oral Deposition of C. Robert Cloninger.
140. Holtzman A. Memo to Horace Kornegay about Tax-Free Cigarettes for Patient Treatment.
141. Torrey EF. Cigarette Donation Request for Long-Term Psychiatric Patients.
142. RJ Reynolds Collection. Letter Declining Request for Cigarette Supply at Saint Elizabeth's Hospital.
143. Buckingham J. Cigarette Request for Day Treatment Program for Mentally Ill Adults.
144. Hayworth P.
145. Robertson ES. Hawaii State Hospital Request to RJ Reynolds for Cigarettes.
146. Ardery PP. Kentucky's Legislators Thank You Letter.
147. Reynolds RJ. West Palm Beach/Ft. Lauderdale Fax for Conference Invites.
148. Shook, Hardy, Bacon Report on Recent ETS and IAQ Developments.
149. Shook, Hardy, Bacon Report on Recent ETS and IAQ Developments.
150. Lyons J. Support of Region III Public Smoking Issues.
151. Doyle JR. Memo to Kent Wold Including the Maine Public Health Association Bulletin.
152. Doyle JR. Letter to Lawrence Tilton about Smoking in Restaurants Bill (L.D. 603) Being Set for Hearing on Wednesday, April 3, 1991.
153. Payne T. Hospital Accreditation.
154. Mental Illness Advocacy Group Battling Hospital Smoking Ban in New York from Psychiatric News
155. Alliance for the Mentally Ill, Friends & Advocates of the Mentally Ill. AMI/ FAMI Policy Paper on Nicotine Addiction and Psychiatric Patients.
156. Alliance for the Mentally Ill, Friends & Advocates of the Mentally Ill. Plea for Freedom to Smoke for Bellevue Hospital Psychiatric Patients.
157. Miller MW. Wall St J. Mental Patients Fight to Smoke in the Hospital.
158. Konopka H. Note to Philip Morris.
159. Konopka H. Hellen Konopka AMI and FAMI Business Card.
160. Philip Morris Collection. Hearing Report/Bill Signing Report.
161. Connelly, McLaughlin Witnesses for Smoke-Free Air Act Hearing. 1994.
162. Foderaro LW. NY Times. Battling demons, and nicotine hospitals’ smoking bans are new anxiety for mentally ill.
163. El-Guebaly N, Cathcart J, Currie S, Brown D, Gloster S. Smoking cessation approaches for persons with mental illness or addictive disorders. Psychiatr Serv. 2002;53:1166–1170. [PubMed] 164. Prochaska JJ, Gill P, Hall SM. Treatment of tobacco use in an inpatient psychiatric setting. Psychiatr Serv. 2004;55:1265–1270. [PubMed] 165. Prochaska JJ, Fletcher L, Hall SE, Hall SM. Return to smoking following a smoke-free psychiatric hospitalization. Am J Addict. 2006;15:15–22. [PubMed] 166. Yano E. Japanese spousal smoking study revisited: how a tobacco industry funded paper reached erroneous conclusions. Tob Control. 2005;14:227–233. discussion 233–235. [PMC free article] [PubMed] 167. Barnes DE, Bero LA. Why review articles on the health effects of passive smoking reach different conclusions. JAMA. 1998;279:1566–1570. [PubMed]
168. US Department of Health Education and Welfare. Smoking and Health: Report of the Advisory Committee of the Surgeon General of the Public Health Service. Washington, DC: US Government Printing Office; 1964.
169. Olincy A, Harris JG, Johnson LL, et al. Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia. Arch Gen Psychiatry. 2006;63:630–638. [PubMed] 170. Harris JG, Kongs S, Allensworth D, et al. Effects of nicotine on cognitive deficits in schizophrenia. Neuropsychopharmacology. 2004;29:8. [PubMed] 171. Smith RC, Warner-Cohen J, Matute M, et al. Effects of nicotine nasal spray on cognitive function in schizophrenia. Neuropsychopharmacology. 2006;31:637–643. [PubMed] 172. Jacobsen LK, D'Souza DC, Mencl WE, Pugh KR, Skudlarksi P, Krystal JH. Nicotine effects on brain function and functional connectivity in schizophrenia. Biol Psychiatry. 2004;55:850–858. [PubMed] 173. Barr RS, Culhane MA, Jubelt LE, et al. The effects of transdermal nicotine on cognition in nonsmokers with schizophrenia and nonpsychiatric controls. Neuropsychopharmacology. 2007 Available at: http://www.ncbi.nlm.nih.gov/sites/entrez. [PubMed]
174. Scriabine A. CNS FORUM Advancements in clinical trials and drug development Philadelphia, PA, USA, July 29–30, 2003. CNS Drug Rev. 2003;9:389–395.
175. Targacept. Press Release: Targacept announces initiation of phase IIb development of AZD3480 (TC-1734) for cognitive deficits in schizophrenia
176. Evins AE, Cather C, Deckersbach T, et al. A double-blind placebo-controlled trial of bupropion sustained-release for smoking cessation in schizophrenia. J Clin Psychopharmacol. 2005;25:218–225. [PubMed]
177. Spiegel EP, Schrock DA, Smith MW. Effectiveness of a Transdermal Nicotine Replacement Intervention in Schizophrenic Smokers. New Orleans, La: American Psychological Association; 2006.
178. Williams JM, Ziedonis DM, Foulds J. A case series of nicotine nasal spray in the treatment of tobacco dependence among patients with schizophrenia. Psychiatr Serv. 2004;55:1064–1066. [PubMed] 179. Dalack GW, Becks L, Hill E, Pomerleau OF, Meador-Woodruff JH. Nicotine withdrawal and psychiatric symptoms in cigarette smokers with schizophrenia. Neuropsychopharmacology. 1999;21:195–202. [PubMed]